A single-cell atlas of brain aging epigenetics has mapped methylation, chromatin, and gene activity changes across 36 cell ...
Oryon Cell Therapies ("Oryon"), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, ...
Orphan designation reflects unmet need in RP rather than evidence of efficacy, while offering development incentives and ...
Sumitomo Pharma America, Inc. (SMPA) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to its investigational therapy DSP-3077 for the treatment of ...
Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement ...
As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results